According to a document submitted to the U.S. Securities and Exchange Commission, an agreement between Arvinas Holding Company LLC and Pfizer indicates that both parties are eligible for milestone payments totaling up to 320 millions USD, along with a tiered royalty structure.

The document further clarifies the conditions and specific terms that trigger payment. Milestone payments will be distributed in phases based on the progress of R&D in the collaborative project, regulatory approvals, and commercialization outcomes at different stages. Tiered royalties mean that as product sales reach different thresholds, the rates will be adjusted accordingly, providing both parties with a more flexible revenue-sharing mechanism. This financial arrangement highlights both parties' confidence in the project's prospects and reflects the risk-sharing and profit-sharing models commonly seen in the biopharmaceutical industry. Although the details of the agreement have not been fully disclosed, the total potential revenue of up to $320 million undoubtedly injects strong financial momentum into the subsequent development of the project.